Week in Review: Fosun, WuXi PharmaTech Acquire San Diego's Ambrx

Fosun Pharma, WuXi PharmaTech and two equity investors will acquire Ambrx, a clinical-stage San Diego antibody-conjugate biotech; Ramsay Sime Darby Health Care, an Australia-Malaysia hospital operator, will pay $135 million to form a five-hospital JV with a Chengdu hospital chain; Livzon Pharma and California's Cynvenio will form a $20 million China JV to offer Cynvenio's blood-based cancer diagnostic in China; China Medical Systems in-licensed greater China rights to Faron Pharma's Traumakine®, a treatment for respiratory distress syndrome; MabSpace, a Hong Kong-Suzhou company, announced deals to discover antibody drug candidates with Shanghai's Genor Biopharma and Jiangsu Hengrui Medicine; WuXi PharmaTech revealed its LabNetwork platform, an e-Commerce site that connects buyers and sellers of research chemicals and reagents; and China announced its plans to scrap the 15% mark-up on drug sales in hospital pharmacies. More details.... Stock Symbols: (SHA: 600196; HK: 02196) (NYSE: WX) (SZE: 200513) (HK: 867) (SHZ: 200513) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.